| 产品描述： | Efaproxiral Sodium , a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer. |
| 靶点： |
Reactive Oxygen Species;ReactiveOxygenSpecies |
| 体内研究： |
Efaproxiral plus oxygen breathing reduces the radiobiological hypoxic fraction of EMT6 tumors from the value of 24% found in both air-breathing and oxygen-breathing mice to 9% and improves the response of the tumors to radiation. Carboplatin (100 mg/kg) slowes tumor growth in air-breathing mice, producing a growth delay of 3.3 days. Efaproxiral plus oxygen increases the growth delay to 5.7 days; this is 2.4 days (71%) greater than that for carboplatin alone and 2.1 days (57%) greater than that for carboplatin plus oxygen breathing. Efaproxiral plus oxygen breathing, therefore, improves the tumor growth delay obtained with 100 mg/kg carboplatin to or beyond that obtained with the highly toxic dose of 150 mg/kg carboplatin, but does so without increasing the toxicity beyond that seen with 100 mg/kg carboplatin in air-breathing mice. Efaproxiral significantly increases tumor oxygenation by 8.4 to 43.4 mmHg within 5 days in C3H mice with RIF-1 tumors, with maximum increases at 22-31 min after treatment. Efaproxiral plus oxygen plus Radiation produces tumor growth inhibition throughout the treatment duration in C3H mice with RIF-1 tumors, and inhibition is significantly different from radiation plus oxygen from day 3 to day 5. |
| 参考文献： |
1.Donnelly ET, et al. Exp Biol Med (Maywood), 2006, 231(3), 317-321. 2.Hou H, et al. Radiat Res, 2007, 168(2), 218-225. |
| 溶解性： |
H2O:67 mg/mL (184.4 mM) DMSO:68 mg/mL (187.1 mM) Ethanol:68 mg/mL (187.1 mM) |
| 保存条件： |
2-8℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.752 ml |
13.76 ml |
27.519 ml |
| 5 mM |
0.55 ml |
2.752 ml |
5.504 ml |
| 10 mM |
0.275 ml |
1.376 ml |
2.752 ml |
| 50 mM |
0.055 ml |
0.275 ml |
0.55 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京